Global Growth Hormone Drugs Market Forecast to 2027

LONDON, December 6, 2017 /PRNewswire/ --

Somatropin and Mecasermin Based Drugs, Innovator Generics and Biosimilars, Norditropin, Genotropin, Humatrope, Saizen, Nutropin, Omnitrope, Zomacton, R&D and Leading Companies

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

     (Logo: http://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg )

In this brand new 184-page report you will receive 78 tables and 106 figures- all unavailable elsewhere.

The 184-page report provides clear detailed insight into the Growth Hormone Drugs Market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

The Global Growth Hormone Drugs market was estimated at $3.8 billion in 2016 and is expected to grow at a CAGR of 3.6% during 2017-2027. Somatropin based drugs led the market with 98.9% of the market share.

Read on to discover how this definitive report can transform your own research and save you time. 

The new market assessment benefits research, analysis and planning in seven main ways:
• World growth hormone drugs market revenue to 2027 - discover that industry's overall sales potential
• Two product classes' revenues to 2027 - investigate categories at world level, finding the most lucrative and promising therapy classes
• Seven leading drugs' revenues to 2027 - find sales predictions for top and emerging products, seeing how agents compete and succeed
• 7 national markets in the Americas, Europe and Asia covered, with forecasts to 2027 - discover the best countries for trade expansion
• Activities of established, rising and emerging companies - hear about firms' products, capabilities, advances, collaborations and outlooks
• R&D for growth hormone medicines - investigate progress in that industry, exploring technological, clinical and commercial opportunities
• Analysis of what stimulates and restrains that industry and market - assess challenges, strengths, competition and opportunities, helping you succeed.

There you explore business intelligence with research, opinions and predictions found only in that work.

Trying our investigation now lets you discover trends, opportunities and prospects
For growth hormone drugs, our report shows you data, trends, opportunities and multilevel sales forecasts. So, avoid missing out. Instead please get that new analysis here now.

Report highlights 

• 184-pages, 78 tables and 106 figures 

• Growth Hormone Drugs Market Forecast from 2017 to 2027 

• This report also breaks down the revenue forecast for the main submarkets:
• Innovator Generics
• Biosimilars
• Mecasermin based drugs
• Somatropin based drugs

Analysis of the Innovator Generics drugs market. Revenue forecasts to 2027 are provided for the following drugs:
• Norditropin
• Genotropin
• Humatrope
• Saizen
• Nutropin

Analysis of the Biosimilar drugs market. Revenue forecasts to 2027 are provided for the following drugs:
• Omnitrope
• Zomactan. Tev-tropin/ Growject

Analysis of key players in Growth Hormone Drugs
• Merck KGaA
• Roche
• Novartis
• Novo Nordisk
• Eli Lilly and Co.
• Pfizer Inc.

Regional Growth Hormone Drugs market forecasts from 2017-2027
• US forecast 2017-2027,
• Japan forecast 2017-2027
• Germany forecast 2017-2027
• UK forecast 2017-2027
• France forecast 2017-2027
• Italy forecast 2017-2027
• Spain forecast 2017-2027

Key questions answered
• How is the Growth Hormone Drugs market evolving?
• What is driving and restraining Growth Hormone Drugs market dynamics?
• How will each Growth Hormone Drugs submarket market grow over the forecast period and how much Sales will these submarkets account for in 2026?
• How will market shares of each Growth Hormone Drugs submarket develop from 2017-2027?
• Which individual technologies will prevail and how will these shifts be responded to?
• Which Growth Hormone Drugs submarket will be the main driver of the overall market from 2017-2027?
• How will political and regulatory factors influence regional Growth Hormone Drugs markets and submarkets?
• Will leading national Growth Hormone Drugs markets broadly follow macroeconomic dynamics, or will individual country sectors outperform the rest of the economy?
• How will market shares of the national markets change by 2026 and which nation will lead the market in 2026?
• Who are the leading players and what are their prospects over the forecast period?
• How will the sector evolve as alliances form during the period between 2017 and 2027?

• Target audience
• Leading Growth Hormone Drug Compaies
• Suppliers
• Contractors
• Technologists
• R&D staff
• Consultants
• Analysts
• CEO's
• CIO's
• COO's
• Business development managers
• Investors
• Governments
• Agencies
• Industry organisations
• Banks

With our study you see how that market can develop and perform, benefiting your reputation for insight and authority.

To request a report overview of this report please contact Sara Peerun at sara.peerun@visiongain.com (+44-(0)-20-7336-6100) or refer to our website:

https://www.visiongain.com/Report/2069/Global-Growth-Hormone-Drugs-Market-Forecast-to-2027

List of Companies and Organisations Mentioned  

Acsendis Pharma

Aeterna Zentaris

Alteogen

Altus Pharmaceuticals

Amgen

Biogenomics

Critical Pharmaceuticals

Eli Lilly and Co

European Medicines Agency (EMA)

Ferring Pharmaceuticals

Food and Drugs Administration (FDA)

FortuneRock

Genentech

GeneScience Pharmaceuticals

Genexine

Hanmi Pharmaceutical

Ipsen

JCR Pharmaceuticals

LG

Merck KGaA

Novartis

Novo Nordisk

Opko Health

Pfenex

Pfizer

Pharmacia and Upjohn

Roche

Roche

Sereno Laboratories

Somatropin BioPartners

Teva

Versatis

World Health Organisation (WHO)

National Institute for Health and Care Excellence (NICE)

To see a report overview please email Sara Peerun on sara.peerun@visiongain.com